Healthcare
Innoviva, Inc.(INVA)
Live Price
Offline$22.74
+1.34% today
1Y Change
+10.40%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $1.48B
- Revenue Growth
- +18.5%
- EPS Growth
- +986.5%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Innoviva, Inc. (INVA) is a Healthcare stock with a market cap of $1.48B and listed on NASDAQ. The stock last traded around $22.74 and up 10.4% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +18.5%, EPS growth of +986.5%, a dividend yield of 0.0%. What stands out right now is revenue +18.5%, EPS +986.5%, free cash flow +3.9% with operating margin -4.0% and ROIC -0.9%. Valuation is more restrained than many high-expectation growth names at P/E 6.3 and price/sales 3.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines INVA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+18.5% vs +7.6% peer median
Operating Margin
Below sector median
-4.0% vs +19.4% peer median
P/E
Below sector median
6.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +18.5% and EPS at +986.5%, with operating margin around -4.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +1.2% | +2.8% | -1.6% |
2026 Feb 25, 2026 | +470.6% | -2.9% | -6.2% | -6.8% |
2025 Nov 5, 2025 | +134.8% | +12.9% | +22.2% | +14.1% |
Benchmark Edge
INVA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INVA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INVA Max Drawdown
-20.32%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INVA and SPY.
Company Overview
Innoviva, Inc.
NASDAQ Global Select
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
- Leadership
- Pavel Raifeld
- IPO Date
- Oct 5, 2004
- Employees
- 127
- Street Address
- 1350 Old Bayshore Highway
- Mailing
- Burlingame, CA, 94010
- Region
- Burlingame, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 238 9600
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 6.3
- EV/EBITDA
- 3.2
- Price/Sales
- 3.6
- Price/Book
- 1.5
Growth
- Revenue
- +18.5%
- EPS
- +986.5%
- Free Cash Flow
- +3.9%
Profitability
- Gross Margin
- 78.9%
- Operating Margin
- -4.0%
- Net Margin
- 65.4%
- ROE
- 30.6%
- ROIC
- -0.9%
Balance Sheet
- Debt/Equity
- 0.23
- Current Ratio
- 14.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.